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A consistent association has been observed between leukocyte telomere length (LTL) and atherosclerosis, but the mechanisms 
underlying these associations are still not well understood. Premature biology aging was evident in atherosclerotic plaques, 
characterized by reduced cell proliferation, irreversible growth arrest and apoptosis, and telomere attrition. As atherosclerosis 
is a state of chronic low-grade inflammation and increased oxidative stress, shortened LTL in patients with atherosclerosis 
might stem from the two sources, one is an accelerated rate in hematopoietic stem cells (HSCs) replication to replace leuko-
cytes consumed in the inflammatory process, and another is the increase in the loss of telomere repeats per replication. Thus, 
diminished HSC reserves at birth and age-dependent telomere attrition afterward are mirrored in shortened LTL during the 
adulthood. In addition, the inter-individual variation of LTL in the general population can be partly explained by genetic fac-
tors regulating telomere maintenance and the rate of HSCs replication. Atherosclerosis is an aging-related disease, and practi-
cally all humans develop atherosclerosis if they live long enough. Here we overview the potential roles of LTL dynamics in the 
imbalance between injurious oxidative stress/inflammation and endothelial repair during the pathogenesis of age-related ather-
osclerosis, and discuss the possibility that preventing accelerated cellular senescence is a potential target in prevention of ath-
erosclerosis. 
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Aging, which is broadly defined as the time-dependent 
functional decline, has attracted curiosity and imagination 
throughout the history of humankind. Atherosclerosis and 
cardiovascular diseases are associated with advanced age, 
and premature vascular aging can be accelerated by cardio-
vascular risk factors, including smoking, alcohol intake, 
diabetes, and dyslipidemia. However, at an individual level 
there is wide variation in the development of atherosclerosis, 
even in individuals with the similar risk factor profiles. The 
reasons why there are inter-individual heterogeneities are 
still incompletely understood, but telomere attrition is rec-
ognized to represent one molecular mechanism underlying 
biological aging and cellular senescence [1]. 
Telomeres are the TTAGGG nucleotide repeats at the 
ends of mammalian chromosomes, which preserve chro-
mosome stability and integrity [2]. Telomeres are progres-
sively shortened with each replication of somatic cells. 
When telomere lengths are shortened to a critical value, 
they lose capping function at the chromosomal ends, result-
ing in activation of DNA damage checkpoints and cell se-
nescence. Emerging epidemiological and experimental evi-
dence has linked leukocyte telomere length (LTL) with 
vascular cell senescence and risk of atherosclerosis and car-
diovascular diseases [3]. However, the question remains 
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unanswered regarding whether telomere length is merely a 
biomarker of atherosclerosis, or an active player in its 
pathogenesis, or both. Here, this review summarizes the 
mechanisms underlying telomere mediated hematopoietic 
senescence and vascular aging in atherosclerosis, and the 
potential therapeutics for cellular senescence. 
1  Normal and premature vascular aging 
Vessel aging, even in the absence of atherosclerosis, can 
lead to vascular remodeling characterized by intimal and 
medial thickening, endothelia cell dysfunction, increased 
collagen deposition, decreased elastin content, and impaired 
vessel elasticity, which hence results in arterial stiffness and 
related vascular diseases. In addition, aged vessels also 
show increased secretion of proinflammatory cytokines and 
uptake of plasma lipoproteins, resulting in persistent vascu-
lar inflammation [4]. Thus, the effects of atherosclerosis are 
superimposed on normal aging of vessels. 
Cell senescence is defined as the irreversible loss of the 
ability of cells to divide, including replicative senescence 
and stress-induced premature senescence (SIPS). Replica-
tive senescence occurs with exhaustion of proliferative 
lifespan over time, and is associated with critically short-
ened telomeres at chromosome ends. In contrast, SIPS is not 
usually characterized by telomere shortening and triggered 
by external stimuli, such as oxidizing agents and radiation, 
which activate the intracellular senescence cascade prema-
turely. Senescent cells are characterized by “specific” 
markers, senescence-associated  galactosidase (SAG), 
and altered expression of cell cycle regulators. Increased 
numbers of SAG-positive vascular smooth cells (VSMCs), 
endothelial cells (ECs), and monocyte/macro- phages are 
observed in aged vessels and atherosclerotic lesions [5,6], 
reinforcing the idea that atherosclerosis is associated with 
premature cellular senescence.  
Does biological aging promote atherosclerosis, or does 
atherosclerosis promote vessel aging and cellular senes-
cence? Obviously, they are not mutually exclusive and both 
occur simultaneously. Recent evidence indicates that pe-
ripheral leukocyte telomere length can be used as a systemic 
marker for cellular senescence and aging-related diseases, 
which might yield new insights into the underlying molecu-
lar mechanisms of vascular aging and improve cardiovas-
cular risk stratification. 
2  Telomere shortening 
Telomere shortening is observed during normal aging and 
premature aging. Telomere length and integrity is mainly 
regulated by telomerase, an enzyme composed of a te-
lomerase RNA component (TERC) and telomerase reverse 
transcriptase (TERT). Generally, telomerase is active only 
in germ lines, during embryogenesis, in adult stem cells and 
in activated immune cells, while most somatic cells repress 
TERT expression at the transcriptional level, suggesting that 
its activity is tightly regulated during development and dif-
ferentiation. Although telomere length results from a dy-
namic balance between elongation and shortening of the 
chromosome ends, mean telomere length within cells is a 
direct indication of the level of telomerase activity. And at 
birth, telomere lengths in most tissues from the same subject 
are similar [7].  
Telomeres are bound by a complex of proteins known as 
Shelterin, including TRF1, TRF2, Rap1, TIN2, PTOP, and 
POT1, which functions to prevent the access of DNA repair 
proteins to the telomeres. Otherwise, telomeres would be 
“repaired” as DNA breaks leading to chromosome fusions. 
Due to their restricted DNA repair, DNA damage at telo-
meres is notably persistent and thus more likely to induce 
cell senescence and/or apoptosis [8].  
Shortened telomeres are evident in atherosclerosis, ob-
served in plaque VSMCs and ECs relative to the normal 
vessel wall, and in circulating EPCs [9]. Shorter telomeres 
and low levels of telomerase expression and activity are 
functionally important in VSMC senescence, because ec-
topic telomerase expression can increase lifespan of both 
plaque and normal VSMCs. In addition, arterial segments 
resistant to atherosclerosis, such as internal mammary artery 
or ascending aorta, have longer telomeres than the aortic 
regions prone to the disease, and the loss of telomeric DNA 
in the aortic regions was found to become more dramatic 
with increasing donor age [10]. This difference can be part-
ly explained by repeated hemodynamic stress to endotheli-
um in the aortic vessels, which is the initiating event to 
vascular dysfunction. The internal thoracic artery is known 
to be subjected to less hemodynamic stress and thus free of 
atherosclerotic plaques even among the elderly. Besides 
hemodynamic injury, it will be of interest to investigate 
whether the existence of intrinsic genetic or developmental 
variations in telomere regulation also underlies loca-
tion-specific predisposition in atherogenesis. 
3  Leukocyte telomere length (LTL) and athe- 
rosclerosis 
Telomere length displays a large inter-individual variation 
at birth and throughout the human lifespan, which is influ-
enced by heredity, gender, race, and environmental expo-
sures. Recent studies have shown that birth LTL is a major 
determinant of LTL at any age, as persons who are born 
with short LTL are likely to display short LTL later in life. 
Thus, individuals who inherited shorter telomeres may dis-
play shorter systemic and vascular telomeres, and are at an 
increased risk for early senescence of vascular tissue, caus-
ing atherosclerosis. This implies that those subjects with 
high-risk predisposition to atherosclerosis and cardiovascu-
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lar diseases could be identified in their early life.  
Emerging epidemiological studies have shown a con-
sistent association between leukocyte telomeres and athero-
sclerosis. Telomere length in leukocytes is shorter in pa-
tients with clinical and subclinical features of atherosclero-
sis compared with control subjects, after adjustment for age, 
sex, and race [1113]. The study by Zhang et al. [14] pro-
vided novel evidence that telomere attrition contributes to 
the presence of both atherothrombotic and hemorrhagic 
stroke in Chinese patients, independent of traditional vas-
cular risk factors. Moreover, their study showed that ath-
erothrombotic stroke patients with shorter telomeres had 
worse prognosis of post-stroke death during the long-term 
follow-up. Studies examining the LTL-mortality relation in 
same-sex elderly twins have found that the co-twins with 
the shorter LTL were more likely to die first during the fol-
low-up period [15]. In addition, persons with multiple vas-
cular risk factors such as high BMI, sedentary lifestyle, in-
sulin resistance or cigarette smoking, also display relatively 
shorter LTL, suggesting that in part the rate of LTL short-
ening is modified by environmental factors.  
Atherosclerosis is an aging-related disease which de-
pends on the balance between the injurious and repair ele-
ments. The injurious element is partially due to the accu-
mulated burden of oxidative stress and chronic low-grade 
inflammation on the vascular endothelium, which can ac-
celerate the pace of age-dependent LTL shortening [16]. 
Another potential mechanism that explains the LTL-   
erosclerosis relation focuses on vascular repair, which is 
largely implemented by endothelial progenitor cells (EPCs) 
originating from the hematopoietic stem cells (HSCs) pool. 
HSCs have insufficient telomerase activity to add telomere 
repeats onto the ends of chromosomes and prevent telomere 
shortening in leukocytes. Thus, diminished HSC reserves at 
birth, their accelerated attrition rate afterward, or both, are 
expressed in the form of shortened LTL during adulthood, 
which confers increased risk for atherosclerosis. This risk is 
largely attributed to insufficient circulating numbers and 
reduced replicative function of EPCs. Consistently, the 
number and proliferative potential of circulating EPCs are 
lower in atherosclerosis and in older person [17]. In this 
way, telomere length in HSCs is both a biomarker of ather-
osclerosis and a determinant of its development. 
4  Genetics of leukocytes telomere length 
Studies in twins, siblings and families have found that LTL 
is heritable with estimated heritability of 0.360.84 [18]. 
Thus, genes that are directly involved in telomere mainte-
nance and those whose function impacts HSC replication 
kinetics may be associated with telomere-related diseases. 
For example, major mutations in TERT and TERC genes 
cause telomerase deficiency and lead to premature devel-
opment of rare monogenic diseases, such as pulmonary fi-
brosis, liver cirrhosis, aplastic anemia, and tumors [19]. 
However, the specific and rare mutations that cause these 
diseases do not explain the wide inter-individual variation 
of LTL in the general population. Only recent genome-wide 
association studies (GWAS) have identified that sin-
gle-nucleotide polymorphisms (SNPs) in loci that harbor 
oligonucleotide/oligosaccharide-binding fold containing 1 
gene (OBFC1), TERC and the chemokine (C-X-C motif) 
receptor 4 gene (CXCR4) are associated with LTL [20,21].  
TERC plays a central role in telomere biology. OBFC1 is 
a newly discovered telomere maintenance gene in humans, 
which functions in the negative regulation of telomerase 
[22]. CXCR4 regulates neutrophil release from the bone 
marrow and plays a key role in the damage-repair feedback 
loop between HSCs and the endothelium, which regulates 
the signals that guide the recruiting of EPCs to the area of 
vascular injury [23]. CXCR4 variants might attenuate the 
rate of HSC replication by slowing the mobilization of neu-
trophils from the bone marrow and thus resulting in a longer 
LTL. Importantly, CXCR4 modulates inflammatory re-
sponse in atherosclerosis [24], and its cognate ligand 
CXCL12 locus was found by GWAS to be associated with 
myocardial infarction [25]. However, it should be noted that 
LTL-regulated genes that have been discovered through 
GWAS explain only a small portion of the inter-individual 
variation in LTL [26]. 
5  Therapy targeting aging in atherosclerosis 
The increasing evidence that accelerated premature cell 
senescence occurs in vascular disease has given an impetus 
to search for treatments that can promote longevity and de-
lay senescence [27,28]. Currently, it is debatable whether 
telomere length and telomerase are targets in atherosclerosis, 
although agents that promote telomere stability in vessel 
cells may be beneficial. First, although atherosclerosis is 
associated with telomere shortening in vascular cells, the 
evidence is lacking to demonstrate that shortening occurs to 
a critical length that impair function, as the rate of LTL 
shortening is rapid during the early life and remains rela-
tively stable during the adulthood (between 20 and 70 years 
of age) when vascular aging is apparent [29]. Second, fur-
ther evidence is needed to reveal whether telomere shorten-
ing initiates atherosclerosis rather than being a feature of 
advanced plaques. Although the lifespan of VSMCs and 
ECs can be extended by ectopic expression of telomerase, it 
is not clear if this is due to effects only on telomere length 
or other causes for their senescence [30]. In addition, the 
animal model studies of telomerase manipulation in athero-
sclerosis are contradictory. Finally and most importantly, 
increasing telomerase expression systemically has the po-
tential risk to be carcinogenic.  
As the rate of age-dependent telomere shortening is ac-
celerated by accumulated burden of oxidative stress and 
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inflammation, a number of currently available drugs and 
compounds are likely to indirectly delay premature aging by 
attenuating ROS and oxidative DNA damage. Such examples 
include antioxidants, statins, and angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin receptor blockers 
(ARBs). Dietary status also has potential to reduce vascular 
aging, cellular senescence, and atherosclerosis. 
6  Conclusion 
In summary, atherosclerosis is a state of chronic imbalance 
in which the injurious effect of oxidative stress/inflamma- 
tion exceeds endothelial repair capacity of HSCs and EPCs, 
which largely depend on telomere length, as expressed in 
LTL. Both normal vascular aging and atherosclerosis are 
associated with cellular senescence. Thus, shortened LTL 
can predict increased atherosclerotic risk as a biomarker of 
atherosclerosis and a determinant of its development. How 
important would it be to record the individual’s LTL dy-
namics from birth to adulthood to old age? It depends on 
whether optimal methods of LTL measurement will be de-
veloped for clinical use, and whether preventive and/or 
therapeutic steps can be guided by LTL results, given that 
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